Toll-like receptor 2 activation by bacterial peptidoglycan-associated lipoprotein activates cardiomyocyte inflammation and contractile dysfunction

Critical Care Medicine

Volumn 35, Issue 3, 2007, Pages 886-892

  Zhu, Xinsheng ^a   Bagchi, Aranya ^a   Zhao, Huailong ^a   Kirschning, Carsten J ^b   Hajjar, Roger J ^a   Chao, Wei ^a   Hellman, Judith ^a   Schmidt, Ulrich ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Peptidoglycan associated lipoprotein; Toll like receptor 2; Tumor necrosis factor

Indexed keywords

CALCIUM ION; CYTOKINE; GAMMA INTERFERON; GRANULOCYTE COLONY STIMULATING FACTOR; LIPOPROTEIN; MYELOID DIFFERENTIATION FACTOR 88; PEPTIDOGLYCAN ASSOCIATED LIPOPROTEIN; TOLL LIKE RECEPTOR 2; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA RECEPTOR; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RECEPTOR 2; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL FUNCTION; CELL ISOLATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; HEART CONTRACTION; HEART DISEASE; HEART FUNCTION; HEART MUSCLE CELL; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; KNOCKOUT MOUSE; MALE; MOUSE; MYOCARDITIS; NONHUMAN; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN EXPRESSION; PROVOCATION TEST; SIGNAL TRANSDUCTION;

ANIMALS; BACTERIAL OUTER MEMBRANE PROTEINS; CALCIUM; ESCHERICHIA COLI PROTEINS; LIPOPROTEINS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MYELOID DIFFERENTIATION FACTOR 88; MYOCARDIAL CONTRACTION; MYOCARDITIS; MYOCYTES, CARDIAC; PEPTIDOGLYCAN; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE II; SIGNAL TRANSDUCTION; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; TOLL-LIKE RECEPTOR 2; TUMOR NECROSIS FACTOR-ALPHA; VENTRICULAR DYSFUNCTION, LEFT;

EID: 33947109614     PISSN: 00903493     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.CCM.0000256723.37586.A2     Document Type: Article

References (35)

1. Kumar A, Haery C, Parrillo JE: Myocardial dysfunction in septic shock: Part I. Clinical manifestation of cardiovascular dysfunction. J Cardiothorac Vasc Anesth 2001; 15:364-376
2. Kumar A, Krieger A, Symeoneides S, et al: Myocardial dysfunction in septic shock: Part II. Role of cytokines and nitric oxide. J Cardiothorac Vasc Anesth 2001; 15:485-511
3. Hellman J, Loiselle PM, Tehan MM, et al: Outer membrane protein A, peptidoglycan-associated lipoprotein, and murein lipoprotein are released by Escherichia coli bacteria into serum. Infect Immun 2000; 68:2566-2572
4. Hellman J, Roberts JD Jr, Tehan MM, et al: Bacterial peptidoglycan- associated lipoprotein is released into the bloodstream in Gram-negative sepsis and causes inflammation and death in mice. J Biol Chem 2002; 277:14274-14280
5. Liang MD, Bagchi A, Warren HS, et al: Bacterial peptidoglycan-associated lipoprotein: A naturally occurring toll-like receptor 2 agonist that is shed into serum and has synergy with lipopolysaccharide. J Infect Dis 2005; 191:939-948
6. Finkel MS, Oddis CV, Jacob TD, et al: Negative inotropic effects of cytokines on the heart mediated by nitric oxide. Science 1992; 257:387-389
7. Evans HG, Lewis MJ, Shah AM: Interleukin-1 beta modulates myocardial contraction via dexamethasone sensitive production of nitric oxide. Cardiovasc Res 1993; 27:1486-1490
8. Meldrum DR: Tumor necrosis factor in the heart. Am J Physiol 1998; 274:R577-R595
9. Murray DR, Freeman GL: Tumor necrosis factor-alpha induces a biphasic effect on myocardial contractility in conscious dogs. Circ Res 1996; 78:154-160
10. Walley KR, Hebert PC, Wakai Y, et al: Decrease in left ventricular contractility after tumor necrosis factor-alpha infusion in dogs. J Appl Physiol 1994; 76:1060-1067
11. Eichenholz PW, Eichacker PQ, Hoffman WD, et al: Tumor necrosis factor challenges in canines: Patterns of cardiovascular dysfunction. Am J Physiol 1992; 263:H668-H675
12. Hellman J, Tehan MM, Warren HS: Murein lipoprotein, peptidoglycan- associated lipoprotein, and outer membrane protein A are present in purified rough and smooth lipopolysaccharides. J Infect Dis 2003; 188:286-289
13. Wooten RM, Ma Y, Yoder RA, et al: Toll-like receptor 2 is required for innate, but not acquired, host defense to Borrelia burgdorferi. J Immunol 2002; 168:348-355
14. Bjorkbacka H, Kunjathoor VV, Moore KJ, et al: Reduced atherosclerosis in MyD88-null mice links elevated serum cholesterol levels to activation of innate immunity signaling pathways. Nat Med 2004; 10:416-421
15. Nikaido H: Isolation of outer membranes. Methods Enzymol 1994; 235:225-234
16. Mizuno T: A novel peptidoglycan-associated lipoprotein (PAL) found in the outer membrane of Proteus mirabilis and other Gramnegative bacteria. J Biochem (Tokyo) 1981; 89:1039-1049
17. Novitsky TJ, Roslansky PF, Siber GR, et al: Turbidimetric method for quantifying serum inhibition of Limulus amoebocyte lysate. J Clin Microbiol 1985; 21:211-216
18. Scherrer-Crosbie M, Steudel W, Ullrich R, et al: Echocardiographic determination of risk area size in a murine model of myocardial ischemia. Am J Physiol 1999; 277:H986-H992
19. Lim CC, Apstein CS, Colucci WS, et al: Impaired cell shortening and relengthening with increased pacing frequency are intrinsic to the senescent mouse cardiomyocyte. J Mol Cell Cardiol 2000; 32:2075-2082
20. Kimura T, Fujita I, Itoh N, et al: Metallothionein acts as a cytoprotectant against doxorubicin toxicity. J Pharmacol Exp Ther 2000; 292:299-302
21. Chao W, Shen Y, Zhu X, et al: Lipopolysaccharide improves cardiomyocyte survival and function after serum deprivation. J Biol Chem 2005; 280:21997-22005
22. Henriksen AZ, Maeland JA: Antibody response to defined domains on enterobacterial outer membrane proteins in healthy persons and patients with bacteraemia. APMIS 1990; 98:163-172
23. Henriksen AZ, Maeland JA: Serum antibodies to outer membrane proteins of Escherichia coli in healthy persons and patients with bacteremia. J Clin Microbiol 1987; 25:2181-2188
24. 2+ handling and shortening in sepsis. Crit Care Med 2005; 33:598-604
25. Ren J, Ren BH, Sharma AC: Sepsis-induced depressed contractile function of isolated ventricular myocytes is due to altered calcium transient properties. Shock 2002; 18:285-288
26. Janssens S, Beyaert R: A universal role for MyD88 in TLR/IL-1R-mediated signaling. Trends Biochem Sci 2002; 27:474-482
27. Meng G, Rutz M, Schiemann M, et al: Antagonistic antibody prevents toll-like receptor 2-driven lethal shock-like syndromes. J Clin Invest 2004; 113:1473-1481
28. Knuefermann P, Sakata Y, Baker JS, et al: Toll-like receptor 2 mediates Staphylococcus aureus-induced myocardial dysfunction and cytokine production in the heart. Circulation 2004; 110:3693-3698
29. Tavener SA, Long EM, Robbins SM, et al: Immune cell Toll-like receptor 4 is required for cardiac myocyte impairment during endotoxemia. Circ Res 2004; 95:700-707
30. Binck BW, Tsen MF, Islas M, et al: Bone marrow-derived cells contribute to contractile dysfunction in endotoxic shock. Am J Physiol Heart Circ Physiol 2005; 288:H577-H583
31. Gershon D: Proteomics technologies: Probing the proteome. Nature 2003; 424:581-587
32. Herbertson MJ, Werner HA, Goddard CM, et al: Anti-tumor necrosis factor-alpha prevents decreased ventricular contractility in endotoxemic pigs. Am J Respir Crit Care Med 1995; 152:480-488
33. Vincent JL, Bakker J, Marecaux G, et al: Administration of anti-TNF antibody improves left ventricular function in septic shock patients: Results of a pilot study. Chest 1992; 101:810-815
34. Cohen J, Carlet J: INTERSEPT: An international, multicenter, placebo-controlled trial of monoclonal antibody to human tumor necrosis factor-alpha in patients with sepsis. International Sepsis Trial Study Group. Crit Care Med 1996; 24:1431-1440
35. Abraham E, Anzueto A, Gutierrez G, et al: Double-blind randomised controlled trial of monoclonal antibody to human tumour necrosis factor in treatment of septic shock: NORASEPT II Study Group. Lancet 1998;351:929-933